The AVERT Sepsis Investigation



Status:Completed
Conditions:Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:18 - Any
Updated:3/16/2015
Start Date:August 2012
End Date:March 2015
Contact:Ryan Arnold, MD
Email:RyArnold@christianacare.org
Phone:(302) 733-4130

Use our guide to learn which trials are right for you!

The AVERT Sepsis Investigation: Assessment of Variability in Early Resuscitation and Treatment of Sepsis

The overall objective of this study is to utilize heart rate variability and respiratory
rate variability in patients with sepsis to predict clinical deterioration and death.

Our specific objectives are:

1. To study the ability of a change in composite variability (∆CVI) assessment to act as a
prognostic aid in predicting disease progression in sepsis.

2. To study the effect that standard resuscitation interventions will have on the
direction and magnitude of ∆CVI in patients with sepsis.

B. Hypotheses H1: In the initial resuscitation of sepsis, a low or declining multi-parameter
composite variability index (CVI) over 4 hours will predict a significant increase in the
combined outcome of overt shock, organ dysfunction, and mortality.

H2: In the initial resuscitation of sepsis, low volume fluid resuscitation (<20 cc/kg) over
4 hours will be associated with a low or declining CVI.


Inclusion Criteria:

- 1. Antibiotics ordered or administered (as surrogate for suspected or confirmed
infection as primary reason for hospital admission as determined by the primary team)
2. Serum lactate ≥ 2.0 mmol/L or transient hypotension (any systolic blood pressure <
100 mmHg).

3. Identification within 12 hours of a qualifying lactate measurement or hypotension
episode 4. Hospital admission planned for suspected infection as primary reasons for
admission (per emergency medicine team).

Exclusion Criteria:

- 1. Age < 18 years 2. Pregnancy 3. Non-sinus cardiac rhythm (atrial fibrillation,
active pacemaker, SVT) 4. Evidence of Overt Shock upon enrollment:

- Hypotension: SBP < 90 mmHg for ≥ 60 minutes

- Any vasopressor or inotrope use (e.g. norepinephrine, dopamine, vasopressin,
dobutamine) 5. Acute respiratory support (BiPAP or mechanical ventilation)
before enrollment 6. Inability to obtain written informed consent from patient
or legally authorized representative 7. Inability to wear Zephyr Bioharness
device
We found this trial at
4
sites
801 North 29th Street
Billings, Montana 59107
406-238-2500
Billings Clinic Based in Billings, Montana, Billings Clinic is a community-governed health care organization consisting...
?
mi
from
Billings, MT
Click here to add this to my saved trials
1 Cooper Plaza
Camden, New Jersey 08103
(856) 342-2000
Cooper University Hospital Cooper University Health Care, the clinical campus of Cooper Medical School of...
?
mi
from
Camden, NJ
Click here to add this to my saved trials
777 Bannock St
Denver, Colorado 80204
(303) 436-6000
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Newark, Delaware 19718
?
mi
from
Newark, DE
Click here to add this to my saved trials